Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Antiplatelet Therapy in Elderly Population: Are the New P2Y12 Inhibitors Safe?

Should elderly patients stick to clopidogrel? The first large study on prasugrel showed an unacceptable increase of bleeding in elderly patients, suggesting the use of 5 mg (although the sample size was small, which hindered the determination of dose efficacy).

Antiagregantes en población añosa

Later, ticagrelor showed better efficacy than clopidogrel without apparent safety concerns. However, specific evidence on elderly populations with infarction has always been limited.

This paper published in Circulation gathered information from 14,005 elderly patients—80 years old and up—included in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry discharged with an indication of aspirin plus clopidogrel (60.2%) or ticagrelor (39.8%) after acute myocardial infarction.

The primary efficacy endpoint was a composite of death, infarction, or stroke, and the primary safety endpoint was bleeding after a 1-year follow-up.

The incidence of the composite primary endpoint of ischemic events was basically identical for ticagrelor and clopidogrel (hazard ratio: 0.97; 95% confidence interval: 0.88–1.06).


Read also: Angioplasty in Aspirin-Free Stable Patients with Prasugrel: Innovation Continues.


When analyzing each individual endpoint, ticagrelor was associated with a 17% higher risk of death and a 48% higher risk of bleeding. At the same time, it presented a 20% lower risk of infarction and an almost 30% lower risk of stroke. The sum of these different risks results in a draw as regards the composite endpoint between ticagrelor and clopidogrel.

A sensitivity analysis in a population <80 years old had different results. For “younger” patients, ticagrelor diminished mortality, infarction, and stroke, without such a pronounced raise in bleeding.

Conclusion

Elderly patients with acute myocardial infarction discharged with ticagrelor show a higher risk of death and bleeding compared to clopidogrel. A randomized study in this population should be conducted.

Original Title: Comparison Between Ticagrelor and Clopidogrel in Elderly Patients with an Acute Coronary Syndrome: Insights from the SWEDEHEART Registry.

Reference: Karolina Szummer et al. Circulation. 2020 Nov 3;142(18):1700-1708. doi: 10.1161/CIRCULATIONAHA.120.050645.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...